Magdalena Żalińska
Gdańsk Medical University(PL)
Publications by Year
Research Areas
Diabetes and associated disorders, Pancreatic function and diabetes, Diabetes Management and Research, Immune Cell Function and Interaction, Phagocytosis and Immune Regulation
Most-Cited Works
- → Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes(2016)99 cited
- → Combined therapy with CD4 + CD25highCD127 − T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ II trial(2022)48 cited
- → Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy(2020)16 cited
- → PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration(2024)11 cited
- → 66-LB: Combined Immunotherapy with T Regulatory Cells and Anti-CD20 Antibody Prolongs Survival of Pancreatic Islets in Type 1 Diabetes(2020)5 cited
- → Changes in Diet and Lifestyle may Lower the Risk of Type 1 Diabetes Mellitus in Children-Environmental Factors Influencing Type 1 Diabetes Mellitus Morbidity(2016)4 cited
- → Assessing the knowledge of the consequences of uncontrolled diabetesin pregnancy and its effects on fetal development, among femaleadolescents with type 1 diabetes(2017)4 cited
- → Insulin secretion in the early phase of type 1 diabetes mellitus (T1DM) and new hopes for maintaining it through therapy(2016)2 cited
- → MOESM1 of Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes(2016)
- → Author response for "Combined therapy with <scp>CD4</scp> + <scp>CD25highCD127</scp> ‐ T regulatory cells and <scp>anti‐CD20</scp> antibody in recent‐onset type 1 diabetes is superior to monotherapy – randomized phase I/ <scp>II</scp> trial"(2022)